Scholarlink

Background <p>Nivolumab plus chemotherapy has shown efficacy in clinical trials for advanced or recurrent gastric cancer (GC). However, real-world utilization data are limited. In this study, we aimed to assess the effectiveness, safety, and treatment status of first line nivolumab plus chemotherapy in Japanese patients with treatment-naïve advanced or recurrent GC.</p> Methods <p>Untreated patients with advanced or recurrent GC who initiated nivolumab plus chemotherapy as first line treatment from November 2021 to June 2023 across 23 Japanese sites were enrolled in this observational study (G-KNIGHT). This report focused on the objective response rate (ORR), real-world progression-free survival (rwPFS), and the treatment-related adverse event (TRAE) incidence. Furthermore, subgroup analyses for ORR and rwPFS were conducted for patients stratified by various factors including age and the programmed cell death ligand 1 (PD-L1) combined positive score (CPS).</p> Results <p>Among 527 patients (median age, 70.3&#xa0;years; 25.2% aged ≥ 75&#xa0;years; 65.5% male; 84.3% with advanced GC), the median follow-up period was 10.4 (interquartile range, 6.7–15.2) months. The ORR was 65.6% (95% confidence interval [CI], 59.9–70.9%). The median rwPFS (months, 95% CI) was 6.9 (6.2–7.6); by subgroups: age &lt; 75&#xa0;years, 6.7 (6.0–7.5); age ≥ 75&#xa0;years, 7.4 (6.2–8.6); PD-L1 CPS &lt; 1, 7.5 (6.5–9.0); CPS 1–5, 6.2 (5.5–8.0); and CPS ≥ 5, 7.0 (6.2–8.2). TRAEs occurred in 91.3% of patients, with 40.4% experiencing grade ≥ 3 events.</p> Conclusions <p>This large-scale real-world study supports the effectiveness and safety of nivolumab plus chemotherapy in untreated Japanese patients with advanced or recurrent GC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月9日

查看全文
  • Shigenori Kadowaki,
  • Tomoyuki Otsuka,
  • Keiko Minashi,
  • Shinichi Nishina,
  • Hiroshi Yabusaki,
  • Chiaki Inagaki,
  • Tomohiro Nishina,
  • Hisateru Yasui,
  • Hiroshi Matsuoka,
  • Nozomu Machida,
  • Masahiro Tsuda,
  • Fumio Nagashima,
  • Hisashi Hosaka,
  • Junichi Matsubara,
  • Hiroyuki Arai,
  • Satoshi Ida,
  • Yuya Kimijima,
  • Yuko Matsuda,
  • Manabu Muto,
  • Kei Muro

摘要

Background

Nivolumab plus chemotherapy has shown efficacy in clinical trials for advanced or recurrent gastric cancer (GC). However, real-world utilization data are limited. In this study, we aimed to assess the effectiveness, safety, and treatment status of first line nivolumab plus chemotherapy in Japanese patients with treatment-naïve advanced or recurrent GC.

Methods

Untreated patients with advanced or recurrent GC who initiated nivolumab plus chemotherapy as first line treatment from November 2021 to June 2023 across 23 Japanese sites were enrolled in this observational study (G-KNIGHT). This report focused on the objective response rate (ORR), real-world progression-free survival (rwPFS), and the treatment-related adverse event (TRAE) incidence. Furthermore, subgroup analyses for ORR and rwPFS were conducted for patients stratified by various factors including age and the programmed cell death ligand 1 (PD-L1) combined positive score (CPS).

Results

Among 527 patients (median age, 70.3 years; 25.2% aged ≥ 75 years; 65.5% male; 84.3% with advanced GC), the median follow-up period was 10.4 (interquartile range, 6.7–15.2) months. The ORR was 65.6% (95% confidence interval [CI], 59.9–70.9%). The median rwPFS (months, 95% CI) was 6.9 (6.2–7.6); by subgroups: age < 75 years, 6.7 (6.0–7.5); age ≥ 75 years, 7.4 (6.2–8.6); PD-L1 CPS < 1, 7.5 (6.5–9.0); CPS 1–5, 6.2 (5.5–8.0); and CPS ≥ 5, 7.0 (6.2–8.2). TRAEs occurred in 91.3% of patients, with 40.4% experiencing grade ≥ 3 events.

Conclusions

This large-scale real-world study supports the effectiveness and safety of nivolumab plus chemotherapy in untreated Japanese patients with advanced or recurrent GC.